Aimee Raleigh is a principal at Atlas Venture where she works alongside stellar entrepreneurs to build companies focused on innovative therapies and exciting new biology. Aimee serves as a board observer for Aiolos Bio, Triveni Bio, Kinaset Therapeutics, HotSpot Therapeutics, Remix Therapeutics, and several stealth newcos. She was previously an observer at Versanis Bio (sold to Eli Lilly).

Prior to joining Atlas, Aimee was a life sciences consultant at L.E.K. Consulting. At L.E.K., she worked with pharmaceutical and biotechnology clients on strategy for early-stage therapies, including asset diligence, pipeline and indication prioritization, and commercial planning. Aimee received her Ph.D. in bioengineering from the University of California, San Diego, where she was mentored by Dr. Robert Sah and Dr. Gary Firestein. Her doctoral work focused on modeling biophysical mechanisms of disrupted synovial joint lubricant homeostasis in post-traumatic osteoarthritis. Aimee received her B.S.E. in biomedical engineering from Duke University, where she researched cell migration in response to chemokine gradients.

In her free time, Aimee enjoys hiking, skiing, and getting lost in a museum or book.